Sanofi SNY announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (“CHMP”) has rendered a positive opinion recommending the approval of its blood cancer drug, ...

Novo Nordisk NVO announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending that Ozempic’s (once-weekly ...

The company formerly known as BeiGene announced that the Committee for Medicinal Products for Human Use (CHMP) has ...

ORION CORPORATION PRESS RELEASE 20 JUNE 2025 at 13.30 EEST CHMP recommends third indication for darolutamide for patients with advanced prostate cancer CHMP adopts positive opinion for the marketing ...

The Committee for Medicinal Products for Human Use (CHMP) has recommended that the drug be approved in combination with bortezomib, lenalidomide and dexamethasone (VRd) as an induction treatment for ...

An EMA committee has recommended approval of Alvotech’s AVT06, a biosimilar to Bayer’s blockbuster ophthalmology drug Eylea.

The CHMP has backed approval of Tecvayli for adults with relapsed and refractory multiple myeloma who have received at least three prior therapies – including an immunomodulatory agent, a ...

If the EMA follows the CHMP’s advice, Zynquista will become the second SGLT-acting drug to be approved for use alongside insulin in type 1 diabetes after AstraZeneca’s SGLT2 inhibitor Forxiga ...

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency ...

The (IMF) and the collaborative stakeholder group i2TEAMM (International Independent Team for Endpoint Approval of Myeloma MRD), which ...

Denosumab biosimilars Vevzuo and Evfraxy are used for treating various bone diseases. The approvals mark a key step in the ...

CHMP adopts positive opinion for the marketing authorisation of darolutamide in combination with androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer ...